An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Drug: Placebo
- Registration Number
- NCT00745615
- Lead Sponsor
- Teva Pharmaceutical Industries, Ltd.
- Brief Summary
This is a multinational, multicenter, randomized, double-blind, parallel-group active extension of LAQ/5062 study (NCT00349193), assessing the tolerability, safety and efficacy of two doses (0.3 mg and 0.6 mg) of laquinimod, orally administered in participants with relapsing remitting multiple sclerosis (RRMS), followed by an open-label phase of laquinimod 0.6 mg daily. This study is LAQ/5063 (i.e., double-blind extension) and LAQ/5063 OL (i.e., subsequent open-label extension). - The first period of the extension study is an active, double-blind period. Participants from the active treatment arms in LAQ/5062 continue their assigned treatment in blinded fashion. Participants who were assigned to placebo treatment in LAQ/5062 are equally randomized in blinded-fashion to laquinimod 0.6 mg or laquinimod 0.3 mg. - Once termination visit of LAQ/5063 active double-blind phase (completion of the full 36 weeks or as requested by the Sponsor) is performed, all participants continue on laquinimod 0.6 mg daily as an open-label intervention. The open-label period continues as long as the Sponsor continues the development of laquinimod 0.6 mg for RRMS or early discontinuation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 257
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Double-Blind: Placebo/Laquinimod 0.3 mg Placebo Participants who will be receiving placebo matching to laquinimod 0.3 mg tablet once daily orally in double-blind core study, will receive laquinimod 0.3 mg tablet once daily orally in double-blind extension period of this study for up to Week 36. Double-Blind: Placebo/Laquinimod 0.6 mg Placebo Participants who will be receiving placebo matching to laquinimod 0.6 mg (2 tablets of placebo) once daily orally in double-blind core study, will receive laquinimod 0.6 mg once daily orally in double-blind extension period of this study for up to Week 36. Double-Blind: Placebo/Laquinimod 0.3 mg Laquinimod Participants who will be receiving placebo matching to laquinimod 0.3 mg tablet once daily orally in double-blind core study, will receive laquinimod 0.3 mg tablet once daily orally in double-blind extension period of this study for up to Week 36. Double-Blind: Laquinimod 0.6 mg Laquinimod Participants who will be receiving laquinimod 0.6 mg (2 tablets of 0.3 mg each) once daily orally in double-blind core study, will continue to receive laquinimod 0.6 mg once daily orally in double-blind extension period of this study for up to Week 36. Double-Blind: Laquinimod 0.3 mg Laquinimod Participants who will be receiving laquinimod 0.3 milligram (mg) tablet once daily orally in double-blind core study, will continue to receive laquinimod 0.3 mg tablet once daily orally in double-blind extension period of this study for up to Week 36. Open Label: Laquinimod 0.6 mg Laquinimod Participants who will be receiving laquinimod 0.6 mg (2 tablets of 0.3 mg each) once daily orally either in double-blind core study or double-blind extension period, will receive laquinimod 0.6 mg capsule once daily orally in open-label extension period of this study until termination (as long as the Sponsor will continue the development of laquinimod 0.6 mg for RRMS) or early discontinuation (up to approximately 10.5 years). Double-Blind: Placebo/Laquinimod 0.6 mg Laquinimod Participants who will be receiving placebo matching to laquinimod 0.6 mg (2 tablets of placebo) once daily orally in double-blind core study, will receive laquinimod 0.6 mg once daily orally in double-blind extension period of this study for up to Week 36. Open-Label: Laquinimod 0.3 mg/Laquinimod 0.6 mg Laquinimod Participants who will be receiving laquinimod 0.3 mg tablet once daily orally either in double-blind core study or double-blind extension period, will receive laquinimod 0.6 mg capsule once daily orally in open-label extension period of this study until termination (as long as the Sponsor will continue the development of laquinimod 0.6 mg for RRMS) or early discontinuation (up to approximately 10.5 years).
- Primary Outcome Measures
Name Time Method Double-Blind Extension Period: Number of Participants With Adverse Events (AEs) Baseline (Week 0) to Week 36 An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
Open-label Extension Period: Number of Participants With AEs Baseline (Month 0/termination visit of double-blind extension phase [completion of full 36 weeks] until termination (as long as the Sponsor continued the development of laquinimod 0.6 mg for RRMS) or early discontinuation (up to approximately 10.5 years) An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
Double-Blind Period: Number of Participants Who Prematurely Discontinued From the Study Due to Any Reason and Due to AEs Baseline (Week 0) to Week 36 An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs.
Open-Label Period: Number of Participants Who Prematurely Discontinued From the Study Due to Any Reason and Due to AEs Baseline (Month 0/termination visit of double-blind extension phase [completion of full 36 weeks] until termination (as long as the Sponsor continued the development of laquinimod 0.6 mg for RRMS) or early discontinuation (up to approximately 10.5 years) An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs.
- Secondary Outcome Measures
Name Time Method Double-Blind Period: Number of New T2 Lesions At the end of active double-blind phase or termination/early termination visit (up to Week 36) Inflammatory disease activity was assessed by MRI measurement of the number of new T2 lesions.
Double-Blind Period: Kurtzke's Expanded Disability Status Scale (EDSS) Score At the end of active double-blind phase or termination/early termination visit (up to Week 36) EDSS (developed by John F. Kurtzke) is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel and bladder, cerebral, and other functions). Each functional system score and an overall score ranges from 0 to 10, where 0 = Normal; 1-1.5 = No disability, but some abnormal neurological signs; 2-2.5 = Minimal disability; 3-4.5 = Moderate disability, affecting daily activities, but can still walk; 5-8 = More severe disability, impairing daily activities and requiring assistance with walking; 8.5-9.5 = Very severe disability, restricting to bed; 10 = Death due to MS. A lower score indicated less disability.
Double-Blind Period: Volume of T2 Lesions At the end of active double-blind phase or termination/early termination visit (up to Week 36) Volume of T2 lesion was assessed by magnetic MRI.
Double-Blind Period: Number of Enhancing Lesions on T1-Weighted Images At the end of active double-blind phase or termination/early termination visit (up to Week 36) Inflammatory disease activity was assessed by magnetic resonance imaging (MRI) measurement of the number of gadolinium-enhanced T1 lesions. T1-weighted scan was taken after administration of gadolinium-gadopentetic acid (Gd-DTPA).
Double-Blind Period: Relapse Rate: Total Number of Confirmed Relapses Baseline (Week 0) up to end of active double-blind phase or termination/early termination visit (up to Week 36) Relapse was defined as the appearance of one or more new neurological abnormalities or the reappearance of one or more previously observed neurological abnormalities, lasting for at least 48 hours (in the absence of fever or any infection) and immediately preceded by an improving neurological state of at least 30 days from onset of previous relapse. An event was counted as a relapse only when the participant's symptoms were accompanied by observed objective neurological changes, consistent with an increase of at least 0.5 in the Expanded disability status scale (EDSS); or one grade in the score of 2 or more of the 7 Functional Systems (FS) (excluding changes in bowel or bladder function or cognition); or 2 grades in the score of one of the FS as compared to the previous evaluation. EDSS assesses disability in 8 functional systems with an overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis \[MS\]).
Double-Blind Period: Percentage of Relapse-Free Participants Baseline (Week 0) up to end of active double-blind phase or termination/early termination visit (up to Week 36) Relapse was defined as the appearance of one or more new neurological abnormalities or the reappearance of one or more previously observed neurological abnormalities, lasting for at least 48 hours (in the absence of fever or any infection) and immediately preceded by an improving neurological state of at least 30 days from onset of previous relapse. An event was counted as a relapse only when the participant's symptoms were accompanied by observed objective neurological changes, consistent with an increase of at least 0.5 in the EDSS; or one grade in the score of 2 or more of the 7 FS (excluding changes in bowel or bladder function or cognition); or 2 grades in the score of one of the FS as compared to the previous evaluation. EDSS assesses disability in 8 functional systems with an overall score ranging from 0 (normal) to 10 (death due to MS).
Double-Blind Period: Number of New Hypointense T1 Lesion on Enhanced T1 Scans At the end of active double-blind phase or termination/early termination visit (up to Week 36) Inflammatory disease activity was assessed by MRI measurement of the number of new hypointense T1 lesions.
Trial Locations
- Locations (45)
Teva Investigational Site 681
🇩🇪Berlin, Germany
Teva Investigational Site 185
🇷🇺St. Petersburg, Russian Federation
Teva Investigational Site 581
🇭🇺Gyula, Hungary
Teva Investigational Site 281
🇵🇱Bydgoszcz, Poland
Teva Investigational Site 186
🇷🇺Moscow, Russian Federation
Teva Investigational Site 187
🇷🇺Moscow, Russian Federation
Teva Investigational Site 181
🇷🇺St. Petersburg, Russian Federation
Teva Investigational Site 380
🇨🇿Praha 2, Czechia
Teva Investigational Site 580
🇭🇺Debrecen, Hungary
Teva Investigational Site 384
🇨🇿Praha 5- Motol, Czechia
Teva Investigational Site 188
🇷🇺Moscow, Russian Federation
Teva Investigational Site 584
🇭🇺Veszprem, Hungary
Teva Investigational Site 981
🇮🇱Ramat -Gan, IL, Israel
Teva Investigational Site 282
🇵🇱Wroclaw, Poland
Teva Investigational Site 486
🇮🇹Milano, Italy
Teva Investigational Site 685
🇩🇪Wuerzburg, Germany
Teva Investigational Site 583
🇭🇺Miskolc, Hungary
Teva Investigational Site 982
🇮🇱Haifa, Israel
Teva Investigational Site 980
🇮🇱Jerusalem, Israel
Teva Investigational Site 483
🇮🇹Cagliari, Italy
Teva Investigational Site 484
🇮🇹Milano, Italy
Teva Investigational Site 488
🇮🇹Siena, Italy
Teva Investigational Site 285
🇵🇱Katowice, Poland
Teva Investigational Site 184
🇷🇺St. Petersburg, Russian Federation
Teva Investigational Site 284
🇵🇱Lublin, Poland
Teva Investigational Site 280
🇵🇱Katowice, Poland
Teva Investigational Site 283
🇵🇱Lodz, Poland
Teva Investigational Site 182
🇷🇺St. Petersburg, Russian Federation
Teva Investigational Site 189
🇷🇺Moscow, Russian Federation
Teva Investigational Site 180
🇷🇺Saint Petersburg, Russian Federation
Teva Investigational Site 881
🇬🇧Sheffield, United Kingdom
Teva Investigational Site 785
🇪🇸Barcelona, Spain
Teva Investigational Site 882
🇬🇧London, United Kingdom
Teva Investigational Site 783
🇪🇸Sevilla, Spain
Teva Investigational Site 684
🇩🇪Erfurt, Germany
Teva Investigational Site 683
🇩🇪Mainz, Germany
Teva Investigational Site 781
🇪🇸Bilbao, Spain
Teva Investigational Site 382
🇨🇿Hradec Kralove 3, Czechia
Teva Investigational Site 687
🇩🇪Hamburg, Germany
Teva Investigational Site 686
🇩🇪Ulm, Germany
Teva Investigational Site 782
🇪🇸Barakaldo, Spain
Teva Investigational Site 784
🇪🇸L'Hospitalet de Llobregat, Spain
Teva Investigational Site 780
🇪🇸Madrid, Spain
Teva Investigational Site 884
🇬🇧Liverpool, United Kingdom
Teva Investigational Site 883
🇬🇧Stoke on Trent, United Kingdom